Jamie Dananberg - 02 Mar 2026 Form 4 Insider Report for Annexon, Inc. (ANNX)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: ANNX
Reported as of: 02 Mar 2026
Net transaction value: -$31,603
SEC form: 4
Accepted by SEC: 04 Mar 2026, 16:30:46 UTC
Prior SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Lew, Attorney-in-Fact

Key filing fact

Jamie Dananberg filed Form 4 for Annexon, Inc. (ANNX) on 04 Mar 2026.

Key facts

This page summarizes Jamie Dananberg's Form 4 filing for Annexon, Inc. (ANNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 23 Feb 2026.
Current net transaction value: -$31,603.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734424 Primary reporting owner

Dananberg Jamie

Relationship: CHIEF MEDICAL OFFICER
Address: C/O ANNEXON, INC., 1400 SIERRA POINT PKWY, BLDG C, STE 200, BRISBANE
Signature: /s/ Jennifer Lew, Attorney-in-Fact
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANNX transaction

Common Stock

Sale

Transaction value: $31,603
Shares: -5,820
Change %: -4.5%
Price: $5.43
Shares after: 123,582
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Footnote F2

This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.